Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - AzurRx BioPharma, Inc. | azrx8k_dec42017.htm |
Exhibit 99.1
AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference
(January 8th)
BROOKLYN, N.Y., Dec. 04, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma,
Inc. (NASDAQ:AZRX)
(“AzurRx” or the “Company”), a company
specializing in the development of non-systemic, recombinant
therapies for gastrointestinal diseases, announced today the
Company will be making a presentation at the Biotech Showcase
conference in San Francisco at the Hilton San Francisco Union
Square Hotel, on Monday, January 8th at 10:00 a.m.
PST.
Thijs Spoor, President and CEO, of AzurRx will provide an overview
of the Company's business during the live presentation and will be
available to participate in one-on-one meetings with investors who
are registered to attend the conference.
About AzurRx BioPharma, Inc.:
AzurRx BioPharma, Inc. (NASDAQ:AZRX)
is engaged in the research and development of non-systemic
biologics for the treatment of patients with gastrointestinal
disorders. MS1819 recombinant lipase for exocrine pancreatic
insufficiency is the Company's lead development program, and
additional early stage research is being conducted for the
prevention of hospital-acquired infections. The Company is
headquartered in Brooklyn, NY, with scientific operations based in
Langlade, France. Additional information on the company can be
found at www.azurrx.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the
meaning of the Private Securities Litigations Reform Act of 1995.
Such statements include, but are not limited to, any statements
relating to our product development programs and any other
statements that are not historical facts. Such statements involve
risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors
that could cause actual results to differ materially from
management's current expectations include those risks and
uncertainties relating to the development and testing of our drug
candidates, the regulatory approval process, our ability to secure
additional financing, the protection of our patent and intellectual
property, the success of strategic agreements and relationships,
and the potential commercialization of any product we may
successfully develop. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
CONTACT:
AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn, NY 11226
Phone: 646.699.7855
www.azurrx.cominfo@azurrx.com
IR contact:
LifeSci Advisors, LLC.
Hans Vitzthum, Managing Director
250 West 55th Street - Suite 16B
New York, NY 10019
Phone: 212-915-2568
www.lifesciadvisors.com
hans@lifesciadvisors.com